Core Insights - The "Ethics and Safety White Paper for Medical Health Large Models" was officially released to provide guidance for the safe, effective, and compliant application of AI in healthcare, promoting the intelligent development of the medical industry [1][2] - The rapid development of AI technology presents significant opportunities in healthcare, but also raises concerns regarding safety, privacy, transparency, and accountability in medical decision-making [1][2] Group 1 - The white paper addresses potential risks in the application of large models, including informed consent, user privacy, data discrimination, opacity, hallucinations, misinformation, and violations of ethical and legal standards [2] - A five-dimensional evaluation system for medical health large models was constructed, focusing on application scenarios, ethical norms, regulatory datasets, assessment points, and subjective questions [2] - The white paper emphasizes a "human-machine alignment" principle, advocating for the integration of this principle into technology development, industry application, and regulation to transform AI from a "high-efficiency tool" to a "reliable partner" [2] Group 2 - The white paper showcases existing applications in the medical industry, such as "Xiao Rui Health," "Quark Health Assistant," and "AI Health Application AQ," which provide various AI functionalities and connect users with over 5,000 hospitals and nearly 1 million doctors [3] - Ant Group integrates ethical principles of equality, respect, trust, and responsibility into the entire technology development process, promoting the idea of "AI for good" [3] - The white paper was developed with contributions from experts across multiple prestigious institutions, ensuring its authority and scientific validity [3]

证券代码：300016 证券简称：北陆药业 债券代码：123082 债券简称：北陆转债 2025 年 6 月 6 日投资者关系活动记录表 编号：【2025】第 018 号 投资者关系 活动类别 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 及人员姓名 天风证券 周海涛 民生加银基金 郝梦娇 时 间 2025 年 6 月 6 日 地 点 线上 上市公司接 待人员姓名 董事会秘书：邵泽慧 投资者关系活动 主要内容介绍 Q1、公司对比剂产品战略布局情况 近年来，公司多项对比剂产品已陆续被纳入国家药品集中采购， 对比剂行业原有的竞争格局和销售模式发生了巨大的变化，为市场参 与者带来压力的同时，也带来了发展的机遇。经过近两年的积极调整， 公司已逐步克服了碘对比剂主打产品管线受集采价格下降带来的巨大 挑战，逐渐出现回暖趋势。 报告期内，公司积极完成碘海醇注射液、碘帕醇注射液、碘克沙 醇注射液的集采执标、接续等工作，努力扩大各产品的市场份额。 公司钆类对比剂产品更加丰富，随着钆特酸葡胺注射液于 2024 年获批，公司已拥有包括钆喷酸葡胺注射液、钆贝葡胺注 ...